Johannes Zanzinger
Direktor/Vorstandsmitglied bei HepaRegeniX GmbH
Profil
Johannes Zanzinger is currently a Director at Eyevensys SAS, Metabomed Ltd., HepaRegeniX GmbH, and DiogenX SAS.
He is also an Investor at Boehringer Ingelheim (Venture Capital).
Previously, he held Director positions at Centauri Therapeutics Ltd.
and AgomAb Therapeutics NV.
He completed his undergraduate degree at the University of Hohenheim.
Aktive Positionen von Johannes Zanzinger
Unternehmen | Position | Beginn |
---|---|---|
HepaRegeniX GmbH
HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | Direktor/Vorstandsmitglied | - |
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Private Equity Investor | 01.05.2019 |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Direktor/Vorstandsmitglied | - |
DiogenX SAS
DiogenX SAS BiotechnologyHealth Technology DiogenX SAS engages in the discovery and development of biologics therapeutics options of Diabetic patients. It operates in Diabetes preclinical stage business segment. The company was founded by Benjamin Charles, Patrick Collombat and Jean Pascal Tranié on December 24, 2019 and is headquartered in Marseille, France. | Direktor/Vorstandsmitglied | - |
Metabomed Ltd.
Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Johannes Zanzinger
Unternehmen | Position | Ende |
---|---|---|
Centauri Therapeutics Ltd.
Centauri Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Centauri Therapeutics Ltd. engages in manufacturing processing drugs in pharmaceutical preparations for life threatening diseases. The firm focuses on on the discovery and development of novel molecules targeting life threatening diseases. The company was founded by Mike Westby and Stuart Lawson and is headquartered in Sandwich, the United Kingdom. | Direktor/Vorstandsmitglied | - |
AgomAb Therapeutics NV
AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Direktor/Vorstandsmitglied | - |
Ausbildung von Johannes Zanzinger
University of Hohenheim | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 7 |
---|---|
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Finance |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Commercial Services |
Metabomed Ltd.
Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Health Technology |
Centauri Therapeutics Ltd.
Centauri Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Centauri Therapeutics Ltd. engages in manufacturing processing drugs in pharmaceutical preparations for life threatening diseases. The firm focuses on on the discovery and development of novel molecules targeting life threatening diseases. The company was founded by Mike Westby and Stuart Lawson and is headquartered in Sandwich, the United Kingdom. | Health Technology |
HepaRegeniX GmbH
HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | Commercial Services |
AgomAb Therapeutics NV
AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Commercial Services |
DiogenX SAS
DiogenX SAS BiotechnologyHealth Technology DiogenX SAS engages in the discovery and development of biologics therapeutics options of Diabetic patients. It operates in Diabetes preclinical stage business segment. The company was founded by Benjamin Charles, Patrick Collombat and Jean Pascal Tranié on December 24, 2019 and is headquartered in Marseille, France. | Health Technology |